Recombinant CBP Monoclonal Antibody (AN301457L)
For research use only.
| Verified Samples |
Verified Samples in WB: 293T nuclear, 293T cytosol Verified Samples in IF: HeLa |
| Dilution | WB 1:1000-1:3000, IF 1:100-1:200 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB, IF |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Synthetic peptide derived from the human CBP protein |
| Abbre | CBP |
| Synonyms | CREBBP, CBP, KAT3A, RSTS, RSTS1, CREB binding protein, CREB-binding protein, Cyclic AMP responsive enhancer binding protein, RTS, Rubinstein Taybi syndrome |
| Swissprot | |
| Calculated MW | 300 kDa |
| Observed MW |
300 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus, Cytoplasm |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Epigenetics and Nuclear Signaling, Microbiology, Stem Cells, Cancer, Metabolism |
| Clone No. | A152 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | CREB-binding protein (CREBBP/CBP), encoded by the human CREBBP gene, is a transcriptional co-activator. CREBBP functions through interactions with transcription factors, mediated by one or more domains: the nuclear receptor interaction domain (RID), the KIX domain (CREB and MYB interaction domain), the cysteine/histidine regions (TAZ1/CH1 and TAZ2/CH3), and the interferon response binding domain. The KIX, TAZ1, and TAZ2 domains of CREBBP bind tightly to the 9aaTADs, the nine amino acid transactivation domains within the tumor suppressor protein p53, thereby influencing its transcriptional activity. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
